This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
64-13-1Relevant articles and documents
ASPARAGINE DERIVATIVES AND METHODS OF USE THEREOF
-
, (2021/12/31)
The present invention relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of them, pharmaceutical compositions comprising them, methods of preparation thereof, intermediate compounds useful for the preparation thereof, and methods of treatment or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using these. (A) (I)
The Synthesis of Primary Amines through Reductive Amination Employing an Iron Catalyst
B?umler, Christoph,Bauer, Christof,Kempe, Rhett
, p. 3110 - 3114 (2020/06/01)
The reductive amination of ketones and aldehydes by ammonia is a highly attractive method for the synthesis of primary amines. The use of catalysts, especially reusable catalysts, based on earth-abundant metals is similarly appealing. Here, the iron-catalyzed synthesis of primary amines through reductive amination was realized. A broad scope and a very good tolerance of functional groups were observed. Ketones, including purely aliphatic ones, aryl–alkyl, dialkyl, and heterocyclic, as well as aldehydes could be converted smoothly into their corresponding primary amines. In addition, the amination of pharmaceuticals, bioactive compounds, and natural products was demonstrated. Many functional groups, such as hydroxy, methoxy, dioxol, sulfonyl, and boronate ester substituents, were tolerated. The catalyst is easy to handle, selective, and reusable and ammonia dissolved in water could be employed as the nitrogen source. The key is the use of a specific Fe complex for the catalyst synthesis and an N-doped SiC material as catalyst support.
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure
Asahina, Yoshikazu,Wurtz, Nicholas R.,Arakawa, Kazuto,Carson, Nancy,Fujii, Kiyoshi,Fukuchi, Kazunori,Garcia, Ricardo,Hsu, Mei-Yin,Ishiyama, Junichi,Ito, Bruce,Kick, Ellen,Lupisella, John,Matsushima, Shingo,Ohata, Kohei,Ostrowski, Jacek,Saito, Yoshifumi,Tsuda, Kosuke,Villarreal, Francisco,Yamada, Hitomi,Yamaoka, Toshikazu,Wexler, Ruth,Gordon, David,Kohno, Yasushi
supporting information, p. 9003 - 9019 (2020/10/18)
Formyl peptide receptor 2 (FPR2) agonists can stimulate resolution of inflammation and may have utility for treatment of diseases caused by chronic inflammation, including heart failure. We report the discovery of a potent and selective FPR2 agonist and its evaluation in a mouse heart failure model. A simple linear urea with moderate agonist activity served as the starting point for optimization. Introduction of a pyrrolidinone core accessed a rigid conformation that produced potent FPR2 and FPR1 agonists. Optimization of lactam substituents led to the discovery of the FPR2 selective agonist 13c, BMS-986235/LAR-1219. In cellular assays 13c inhibited neutrophil chemotaxis and stimulated macrophage phagocytosis, key end points to promote resolution of inflammation. Cardiac structure and functional improvements were observed in a mouse heart failure model following treatment with BMS-986235/LAR-1219.